MCID: GLC025
MIFTS: 23

Galactorrhoea-Hyperprolactinaemia

Categories: Rare diseases

Aliases & Classifications for Galactorrhoea-Hyperprolactinaemia

MalaCards integrated aliases for Galactorrhoea-Hyperprolactinaemia:

Name: Galactorrhoea-Hyperprolactinaemia 54
Galactorrhea-Hyperprolactinemia 54 74
Hyperprolactinaemia 54

Classifications:



External Ids:

UMLS 74 C2930894

Summaries for Galactorrhoea-Hyperprolactinaemia

MalaCards based summary : Galactorrhoea-Hyperprolactinaemia, also known as galactorrhea-hyperprolactinemia, is related to hyperprolactinemia and ahumada del castillo syndrome. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and ovary.

Related Diseases for Galactorrhoea-Hyperprolactinaemia

Diseases related to Galactorrhoea-Hyperprolactinaemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 hyperprolactinemia 12.0
2 ahumada del castillo syndrome 11.2
3 pituitary adenoma, prolactin-secreting 10.8
4 hypogonadism 10.3
5 hypogonadotropism 10.3
6 hypothyroidism 10.2
7 hyperostosis frontalis interna 10.2
8 hyperostosis 10.2
9 pituitary adenoma 10.2
10 adenoma 10.2
11 schizophrenia 10.2
12 infertility 10.1
13 renal tubular acidosis 10.1
14 male infertility 10.1
15 lymphoma 10.0
16 impotence 10.0
17 anovulation 10.0
18 hypopituitarism 10.0
19 diabetes insipidus 10.0
20 breast cancer 9.8
21 hypertension, essential 9.8
22 osteoporosis 9.8
23 mccune-albright syndrome 9.8
24 prostate cancer 9.8
25 autism 9.8
26 galactorrhea 9.8
27 lymphoma, hodgkin, classic 9.8
28 pituitary hormone deficiency, combined, 2 9.8
29 prostate cancer, hereditary, 8 9.8
30 lymphoma, non-hodgkin, familial 9.8
31 prostate cancer, hereditary, 6 9.8
32 peripartum cardiomyopathy 9.8
33 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
34 arthritis 9.8
35 heart valve disease 9.8
36 temporal lobe epilepsy 9.8
37 chikungunya 9.8
38 congenital hypothyroidism 9.8
39 autism spectrum disorder 9.8
40 sexual disorder 9.8
41 glucose intolerance 9.8
42 lactocele 9.8
43 abducens nerve disease 9.8
44 opioid abuse 9.8
45 heart disease 9.8
46 constrictive pericarditis 9.8
47 leiomyoma 9.8
48 pedophilia 9.8
49 amenorrhea 9.8
50 pericarditis 9.8

Graphical network of the top 20 diseases related to Galactorrhoea-Hyperprolactinaemia:



Diseases related to Galactorrhoea-Hyperprolactinaemia

Symptoms & Phenotypes for Galactorrhoea-Hyperprolactinaemia

Drugs & Therapeutics for Galactorrhoea-Hyperprolactinaemia

Drugs for Galactorrhoea-Hyperprolactinaemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 62-31-7, 51-61-6 681
3
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
4
Cabergoline Approved Phase 4,Not Applicable 81409-90-7 54746
5
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Amantadine Approved Phase 4 768-94-5 2130
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
10 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
12 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
13 Dopamine D2 Receptor Antagonists Phase 4,Not Applicable
14 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
15 Serotonin Agents Phase 4,Phase 3,Not Applicable
16 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antidepressive Agents Phase 4,Phase 3,Not Applicable
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
19 Serotonin 5-HT2 Receptor Antagonists Phase 4,Not Applicable
20 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Serotonin Receptor Agonists Phase 4,Not Applicable
24 Paliperidone Palmitate Phase 4
25 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
28 Estradiol 3-benzoate Phase 4
29 Estradiol 17 beta-cypionate Phase 4
30 Antiviral Agents Phase 4
31 Analgesics Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Anti-Infective Agents Phase 4
34
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 50-67-9 5202
35
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
36
Calcium Carbonate Approved, Investigational Phase 3 471-34-1
37
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 1406-16-2
39
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
40 Hormone Antagonists Phase 3,Phase 2
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
42 Vitamins Phase 3,Not Applicable
43 Calcium, Dietary Phase 3,Phase 2
44 Vitamin D2 Phase 3
45 Ergocalciferols Phase 3
46 Bone Density Conservation Agents Phase 3
47 Anti-Ulcer Agents Phase 3
48 Trace Elements Phase 3
49 Antacids Phase 3
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
11 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
12 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3 Quetiapine XR;Risperidone
13 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2 PGD granules;Placebo
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
15 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
16 Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Not yet recruiting NCT03709849 Phase 2 experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo;control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
17 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
18 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Unknown status NCT02092129
19 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232 Not Applicable Aripiprazole
20 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
21 TSH And AMH in Infertile Women Unknown status NCT02710175
22 Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Completed NCT03569787
23 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
24 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298 Not Applicable Aripiprazole;Placebo
25 Characterization of Macroprolactinemia Completed NCT00436111
26 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
27 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711 Study Drug
28 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
29 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
30 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
31 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
32 Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) Completed NCT01495741
33 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
34 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
35 Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors Completed NCT01568359
36 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
37 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
38 Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism Recruiting NCT03675750
39 Radial Shockwave Therapy for Erectile Dysfunction Recruiting NCT03596047 Not Applicable
40 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
41 Assessing Fertility Potential in Female Cancer Survivors Active, not recruiting NCT01143844
42 Effects of Exercise and Yogurt on Bone Mineral Density and Immunological Factors in Human Milk: The MEEMA Study Not yet recruiting NCT03732261 Not Applicable
43 Pituitary Function and Spontaneous Intracranial Hypotension Suspended NCT02603549
44 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Withdrawn NCT00699530

Search NIH Clinical Center for Galactorrhoea-Hyperprolactinaemia

Genetic Tests for Galactorrhoea-Hyperprolactinaemia

Anatomical Context for Galactorrhoea-Hyperprolactinaemia

MalaCards organs/tissues related to Galactorrhoea-Hyperprolactinaemia:

42
Pituitary, Bone, Ovary, Endothelial, Breast, Heart, Thyroid

Publications for Galactorrhoea-Hyperprolactinaemia

Articles related to Galactorrhoea-Hyperprolactinaemia:

# Title Authors Year
1
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. ( 11273087 )
2001
2
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. ( 11273088 )
2001
3
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. ( 11273089 )
2001
4
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. ( 11273090 )
2001
5
Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. ( 6700889 )
1984
6
Hyperostosis frontalis, galactorrhoea/hyperprolactinaemia, and Morgagni-Stewart-Morel syndrome. ( 6131191 )
1983
7
Galactorrhoea, hyperprolactinaemia, and pituitary adenoma presenting during metoclopramide therapy. ( 7202198 )
1982
8
Amenorrhea, galactorrhea, hyperprolactinemia syndrome and breast carcinoma in a young woman. ( 7194824 )
1981
9
Pituitary function testing in amenorrhea-galactorrhea-hyperprolactinemia. ( 115722 )
1979
10
Primary empty sella, galactorrhea, hyperprolactinemia and renal tubular acidosis. ( 1190258 )
1975

Variations for Galactorrhoea-Hyperprolactinaemia

Expression for Galactorrhoea-Hyperprolactinaemia

Search GEO for disease gene expression data for Galactorrhoea-Hyperprolactinaemia.

Pathways for Galactorrhoea-Hyperprolactinaemia

GO Terms for Galactorrhoea-Hyperprolactinaemia

Sources for Galactorrhoea-Hyperprolactinaemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....